Aminov Erez 4

What Happened

• Erez Aminov, CEO, Chairman and a director of Telomir Pharmaceuticals (TELO), was granted new derivative awards (options) covering 1,960,170 shares and 2,000,000 shares (total 3,960,170) on 2026-05-21. The filing also shows dispositions to the issuer for the same amounts on the same date, indicating cancellation of prior option grants in exchange for these new awards.
• No exercise prices or dollar values are listed in the filing (marked N/A). Footnotes state the new options are fully exercisable (F1) and that Aminov agreed to cancellation of options granted on 08/27/2024 and 05/27/2025 in exchange for the new options with a lower exercise price (F2). This is a derivative (options) transaction, not an open‑market buy or sale.

Key Details

• Transaction date: 2026-05-21; Form filed: 2026-05-22 (timely).
• Grants: 1,960,170 and 2,000,000 option awards (total 3,960,170). Dispositions to issuer match those amounts (cancellations).
• Prices/values: Not disclosed (N/A) in the filing.
• Options status: Fully exercisable per footnote.
• Shares owned after transaction: Not reported in the provided data.
• Filing timeliness: Reported the next day; not flagged as late.

Context

• These entries reflect an option cancellation and replacement (repricing) rather than a purchase or sale of common stock. Because exercise prices are not disclosed here, the financial impact (value to the insider) cannot be determined from this Form 4 alone.
• For retail investors: option grants/reprisings adjust executive incentive terms but do not necessarily indicate immediate buying or selling of shares; monitor future Forms (exercises or open‑market trades) for more direct insider buying/selling signals.